Neuropharmacology & Neurotherapeutics
Gabapentin
Sep. 12, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
10.14.2024
Several high-cost biologicals have been approved for use in treating neurologic disorders, reflecting the complexity and expense of developing and producing these therapies. Below are a few examples, along with the expected annual cost for patients and a discussion of the implications for the healthcare system.
1. Ocrevus® (ocrelizumab)
2. Spinraza® (nusinersen)
3. Zolgensma® (onasemnogene abeparvovec)
4. Soliris® (eculizumab)
Healthcare system implications
The introduction of these high-cost biologicals presents significant challenges to healthcare systems worldwide. The financial burden of these drugs can lead to increased insurance premiums, higher out-of-pocket costs for patients, and tough decisions about which treatments to cover. For public healthcare systems, the cost of these drugs can lead to budget constraints, forcing trade-offs between funding for high-cost biologicals and other essential healthcare services.
In addition to financial challenges, the high cost of these treatments can also limit access, particularly in lower-income countries or for patients without comprehensive insurance coverage. This raises ethical concerns about equity in healthcare and the need for policies that ensure that all patients, regardless of their financial situation, can access life-saving treatments.
As more high-cost biologicals are developed, there is an increasing need for innovative payment models, such as outcome-based pricing, to ensure that these drugs are affordable and accessible while still incentivizing pharmaceutical companies to invest in developing new therapies.
Related MedLink Neurology Podcast content:
MedLink acknowledges the use of ChatGPT-4, an Artificial Intelligence chatbot, in drafting this blog entry.
Are you interested in being a guest blogger for MedLink Neurology? Contact us at editorial@medlink.com.
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125